Advertisement

Topics

FDA Approves Gattex for Children One Year of Age and Older with Short Bowel Syndrome

10:16 EDT 17 May 2019 | Speciality Pharma Journal

LEXINGTON, Mass., May 17, 2019 /PRNewswire/ — Takeda Pharmaceuticals, U.S.A., Inc. (“Takeda”), announced today that the U.S. Food and Drug Administration (FDA) approved extending the indication of GATTEX® (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding …

Original Article: FDA Approves Gattex for Children One Year of Age and Older with Short Bowel Syndrome

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Gattex for Children One Year of Age and Older with Short Bowel Syndrome"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...